Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Next Previous
X
Search
Trial Profile

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceralasertib (Primary) ; Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms DASH trial

    • Most Recent Events

    • 06 Jun 2024 Planned number of patients changed from 15 to 51.
    • 02 Jul 2021 Status changed from not yet recruiting to recruiting.
    • 02 Jul 2021 Planned End Date changed from 8 Mar 2023 to 31 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top